GerkenT, GirardCA, TungYC, et al.: The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science, 2007; 318:1469–1472.
2.
ScuteriA, SannaS, ChenWM, et al.: Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet, 2007; 3:e115.
3.
FischerJ, KochL, EmmerlingC, et al.: Inactivation of the Fto gene protects from obesity. Nature, 2009; 458:894–898.
4.
DoaeiS, Mosavi JarrahiSA, Sanjari MoghadamA, et al.: The effect of rs9930506 FTO gene polymorphism on obesity risk: a meta-analysis. Biomol Concepts, 2019; 10:237–242.
5.
EbellMH: Lorcaserin is safe, but only modestly effective for weight loss. Am Fam Physician 2019;99:Online. https://www.aafp.org/afp/2019/0315/od4.html (Last accessed January29, 2020).
6.
OuchiM, KittaT, KannoY, et al.: Effect of a 5-HT2c receptor agonist on urethral closure mechanisms in female rats. Neurourol Urodyn, 2018; 37:2382–2388.
7.
ToleteP, KnuppK, KarlovichM, et al.: Lorcaserin therapy for severe epilepsy of childhood onset: a case series. Neurology, 2018; 91:837–839.
8.
PirtleJL, HickmanMD, BoinpellyVC, SurineniK, ThakurHK, GrasingKW: The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: a randomized, controlled human laboratory study. Pharmacol Biochem Behav, 2019; 180:52–59.
9.
KimSE, KimJG, ParkK: Biomaterials for the treatment of tendon injury. Tissue Eng Regen Med, 2019; 16:467–477.
10.
SuzawaH, KikuchiS, AraiN, KodaA: The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol, 1992; 60:91–96.
11.
HuZ, ChenB, LiY, et al.: Effect of tranilast on wound healing and administration time on scar hyperplasia of deep partial-thickness burn in mice. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2017; 31:465–472.
12.
LiuY, KanM, LiA, et al.: Inhibitory effects of tranilast on cytokine, chemokine, adhesion molecule, and matrix metalloproteinase expression in human corneal fibroblasts exposed to Poly(I:C). Curr Eye Res, 2016; 41:1400–1407.
13.
ShiTT, YuXX, YanLJ, XiaoHT. Research progress of hydroxychloroquine and autophagy inhibitors on cancer. Cancer Chemother Pharmacol, 2017; 79:287–294.
14.
CookKL, WärriA, Soto-PantojaDR, et al.: Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res, 2014; 20:3222–3232. [Correction in: Clin Cancer Res 2016;20:2825].
15.
WangP, DuY, WangJ: Identification of breast cancer subtypes sensitive to HCQ-induced autophagy inhibition. Pathol Res Pract, 2019; 215:152609.
16.
ShuklaAM, ShuklaAW: Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context, 2019; 8;pii:2019-9-1.
17.
HayashiG, CortopassiG: Lymphoblast oxidative stress genes as potential biomarkers of disease severity and drug effect in Friedreich's ataxia. PLoS One, 2016; 11:e0153574.
18.
KhdourOM, BandyopadhyayI, ChowdhurySR, VisavadiyaNP, HechtSM: Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia. Bioorg Med Chem, 2018; 26:3359–3369.
19.
BellKF, Claudio CuelloA: Altered synaptic function in Alzheimer's disease. Eur J Pharmacol, 2006; 545:11–21.
20.
ChumakovI, NabirotchkinS, CholetN, et al.: Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy. Sci Rep, 2015; 5:7608.
21.
TamirS, PaddockML, Darash-Yahana-BaramM, et al.: Structure-function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease. Biochim Biophys Acta, 2015; 1853:1294–1315.
22.
KarmiO, MarjaultHB, PesceL, et al.: The unique fold and lability of the [2Fe-2S] clusters of NEET proteins mediate their key functions in health and disease. J Biol Inorg Chem, 2018; 23:599–612.
23.
LipperCH, KarmiO, SohnYS, et al.: Structure of the human monomeric NEET protein MiNT and its role in regulating iron and reactive oxygen species in cancer cells. Proc Natl Acad Sci USA, 2018; 115:272–277.
24.
GeldenhuysWJ, YonutasHM, MorrisDL, SullivanPG, DarveshAS, LeeperTC: Identification of small molecules that bind to the mitochondrial protein mitoNEET. Bioorg Med Chem Lett, 2016; 26:5350–5353.
25.
KaplanJM, ZingarelliB, KrallmanK, et al.: Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. Intensive Care Med, 2018; 44:2006–2008.
26.
McCarthyCP, MullinsKV, KerinsDM: The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. Eur Heart J Cardiovasc Pharmacother, 2016; 2:266–272.
27.
ThadaniU: Trimetazidine for stable and unstable ischemic heart diseases and for heart failure: is its routine use justified from available data?. Int J Cardiol, 2019; 300:45–46.
28.
YangY, LiN, ChenT, ZhangC, LiuL, QiY, BuP: Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway. Pharm Biol, 2019; 57:625–631.
29.
KarahanG, KayaH, ErdoganMA, YigitturkG, GokyaylaE, ErbasO: Effects of trimetazidine on nerve regeneration in a rat sciatic nerve injury model. Bratisl Lek Listy, 2019; 120:777–782.
30.
SinghM, AlaviA, WongR, AkitaS: Radiodermatitis: a review of our current understanding. Am J Clin Dermatol, 2016; 17:277–292.
31.
GhebremariamYT, CookeJP, GerhartW, et al.: Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med, 2015; 13:249.
32.
WangT, HuP, LiB, ZhangJP, ChengYF, LiangYM: Role of Nrf2 signaling pathway in the radiation tolerance of patients with head and neck squamous cell carcinoma: an in vivo and in vitro study. Onco Targets Ther, 2017; 10:1809–1819.
33.
PhamN, LudwigMS, WangM, et al.: Topical esomeprazole mitigates radiation-induced dermal inflammation and fibrosis. Radiat Res, 2019; 192:473–482.
34.
YoungA, NamasR, DodgeC, KhannaD: Hand impairment in systemic sclerosis: various manifestations and currently available treatment. Curr Treatm Opt Rheumatol, 2016; 2:252–269.
35.
ShipmanL: Connective tissue diseases: digital ulcers unaffected by endothelin blockade. Nat Rev Rheumatol, 2016; 12:374.
36.
de Vries-BouwstraJK, AllanoreY, Matucci-CerinicM, Balbir-GurmanA: Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis. J Rheumatol, 2019. [Epub ahead of print]; DOI: 10.3899/jrheum.181173.
37.
Shi-WenX, DentonCP, DashwoodMR, et al.: Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol, 2001; 116:417–425.
38.
Carrillo-SalinasFJ, NgwenyamaN, AnastasiouM, KaurK, AlcaideP: Heart inflammation: immune cell roles and roads to the heart. Am J Pathol, 2019; 189:1482–1494.
39.
WeiratherJ, HofmannUD, BeyersdorfN, RamosGC, VogelB, FreyA: Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res, 2014; 115:55–67.
40.
MengX, YangJ, DongM, et al.: Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol, 2016; 13:167–179.
41.
LaiSL, Marín-JuezR, MouraPL, et al.: Reciprocal analyses in zebrafish and medaka reveal that harnessing the immune response promotes cardiac regeneration. Elife, 2017; 6:pii: e25605.
42.
BrænneI, ZengL, WillenborgC, et al.: Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. PLoS One, 2017; 12:e0182999.
43.
KjaergaardN, KjaergaardB, LauritsenJG. Prazosin, an adrenergic blocking agent inadequate as male contraceptive pill. Contraception, 1988; 37:621–629.
44.
CakirogluB, HazarAI, SinanogluO, ArdaE, EkiciS: Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation. Arch Ital Urol Androl, 2017; 89:31–33.
45.
HisasueS, FuruyaR, ItohN, KobayashiK, FuruyaS, TsukamotoT: Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol, 2006; 13:1311–1316.
46.
BhatGS, ShastryA: A prospective double-blind, randomized, placebo-controlled study to evaluate the efficacy of silodosin 8 mg as an on-demand, reversible, nonhormonal oral contraceptive for males: a pilot study. World J Urol, 2019. [Epub ahead of print]; DOI: 10.1007/s00345-019-02806-7.